Paul Raymond Young, M.D. Otolaryngology - Plastic Surgery within the Head & Neck Medicare: Accepting Medicare Assignments Practice Location: 4955 N Bailey Ave, Suite 202, Amherst, NY 14226 Phone: 716-832-8500 Fax: 716-832-8501 |
Dr. Edward Niemiec, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 315 Alberta Dr, Amherst, NY 14226 Phone: 716-833-5100 Fax: 716-833-5102 |
News Archive
As part of its commitment to innovation and improving patient outcomes, Boston Scientific Corporation has initiated the PLATINUM Diversity trial to evaluate the clinical performance of the Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System in underserved patient populations, including women and people of color.
Understanding the mechanisms that mediate widespread DNA damage in the cancer genome is of great interest to cancer physicians and scientists because it may lead to improved treatments and diagnosis. In this study, a multi-institutional team led by researchers at Baylor College of Medicine has brought attention to genomic structural variation as a previously unappreciated mechanism involved in altering DNA methylation, a form of gene control, in human cancers.
A relatively new ultrasound probe procedure has the highest success rate for breaking down kidney stones in the lower "funnel" area of the kidney, rather than the shock wave treatment used for many years, according to a review of studies.
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic diseases, today announced that Dr. Rebecca Taub, Senior Vice President Research & Development will present "Liver Directed Beta Agonist for Targeting Cardiometabolic Disease", and will discuss the Company's cardio-metabolic product portfolio, including VIA's inhibitor of 5 Lipoxygenase, its THR Beta Agonist, and its DGAT1 development programs, at the Cambridge Healthtech Institute Seventh International Discovery on Target 2009 program, on November 3, 2009 in Boston, MA.
New research suggests the modulation of lysosomal-immune pathways may present a novel drug-targeting strategy to attenuate SARS-CoV-2 infections.
› Verified 3 days ago